Goldman Sachs Group says its private credit fund narrowly escaped a broader exodus due to its reliance on institutional investors. Goldman Sachs Private Credit, which manages a so-called non-traded business development company, met redemption requests in the first quarter amounting to 4.999% of its outstanding shares. That contrasts with peers including Blue Owl Capital that saw redemption request...
Goldman Sachs Group says its private credit fund narrowly escaped a broader exodus due to its reliance on institutional investors. Goldman Sachs Private Credit, which manages a so-called non-traded business development company, met redemption requests in the first quarter amounting to 4.999% of its outstanding shares. That contrasts with peers including Blue Owl Capital that saw redemption requests dramatically higher than an industry-wide 5% limit. Bloomberg's Neil Callanan breaks down the situation. (Source: Bloomberg)
Intel Corp. (NASDAQ:INTC) is one of the 10 best AI chip stocks to buy according to hedge funds. On April 2, Reuters reported that Intel Corp. (NASDAQ:INTC) announced plans for investing an extra $15 million in Samba Nova Systems, a chip startup that is led by the company’s CEO Lip-Bu Tan. This investment will see […]
Intel Corp. (NASDAQ:INTC) is one of the 10 best AI chip stocks to buy according to hedge funds. On April 2, Reuters reported that Intel Corp. (NASDAQ:INTC) announced plans for investing an extra $15 million in Samba Nova Systems, a chip startup that is led by the company’s CEO Lip-Bu Tan. This investment will see […]
After NuScale Power (NYSE: SMR) stock plunged 26.5% in February, investors had high hopes the nuclear energy stock would recover in March. Sadly for them, though, this didn't come to pass for two reasons. For one, NuScale Power reported disappointing fourth-quarter 2025 financial results in late February, which prompted bears to sell NuScale Power stock in the subsequent weeks. Secondly, several f...
After NuScale Power (NYSE: SMR) stock plunged 26.5% in February, investors had high hopes the nuclear energy stock would recover in March. Sadly for them, though, this didn't come to pass for two reasons. For one, NuScale Power reported disappointing fourth-quarter 2025 financial results in late February, which prompted bears to sell NuScale Power stock in the subsequent weeks. Secondly, several firms announced more pessimistic outlooks on NuScale Power stock. These two catalysts proved to be too formidable -- and shares tumbled last month. According to data provided by S&P Global Market Intelligence , shares of NuScale Power dropped 15.6% in March. Image source: Getty Images. Continue reading
Jacob Wackerhausen/iStock via Getty Images Last year, when I reiterated the case for buying Phreesia ( PHR ) , I set my next purchase point conditional on a stock recovery above its 200-day moving average (DMA). That rebound never happened, and the stock delivered a fresh reminder of the importance of technical signals between earnings reports. The market was unhappy with last year’s acquisition o...
Jacob Wackerhausen/iStock via Getty Images Last year, when I reiterated the case for buying Phreesia ( PHR ) , I set my next purchase point conditional on a stock recovery above its 200-day moving average (DMA). That rebound never happened, and the stock delivered a fresh reminder of the importance of technical signals between earnings reports. The market was unhappy with last year’s acquisition of AccessOne, and displeasure accelerated with the stock plunging 26.6% after Q4 2026 earnings. Investors took no solace in the company’s major milestone in achieving full-year positive GAAP net income for the first time. Instead, downwardly revised revenue guidance and looming investments in AccessOne combined to undermine support for the stock. This vote of no confidence will take several quarters or more to repair. In the meantime, I have downgraded the stock from a buy to a hold. PHR is trading at all-time lows after plunging below its previous trading range. (TradingView) Guidance Last year, the company’s guidance was part of my bullish case for the stock. Now, the guidance has helped invalidate the bullish case. Phreesia lowered guidance for fiscal 2027 from a range of $545M to $559M to a range of $510M to $520M, a decline of 6.7% at the midpoint. Since the company has “shorter visibility into spending commitments by certain pharmaceutical manufacturers” and recently suffered “even lower levels of dollars committed by certain Network Solutions clients for the second half of the fiscal year,” I am not expecting upside surprises in the coming year. Network Solutions is Phreesia’s top-ranked grower in the business, followed by payments and then subscriptions. Guidance for total revenue per Average Healthcare Services Client (AHSC) also fell, a key normalized metric for assessing Phreesia’s growth. The revenue headwinds forced the company to reduce revenue per AHSC guidance from a low double-digit range to a low single-digit percentage range. Surprisingly, the company left...